Facts and controversies in the use of trastuzumab in the adjuvant setting

Nature Clinical Practice Oncology

Volumn 5, Issue 11, 2008, Pages 645-654

  Dinh, Phuong ^a   de Azambuja, Evandro ^a   Cardoso, Fatima ^a   Piccart Gebhart, Martine J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ETOPOSIDE; METHOTREXATE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; GENE EXPRESSION; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BELGIUM; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; RECEPTOR, ERBB-2; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 55549120522     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1219     Document Type: Review

References (49)

1. Slamon DJ et al. (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182
2. Slamon DJ et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712
3. Slamon DJ et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792
4. Marty M et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23: 4265-4274
5. Piccart-Gebhart MJ et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 1659-1672
6. Smith I et al. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer: A randomized controlled trial. Lancet 369: 29-36
7. Romond EH et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684
8. Perez EA et al. (2005) NCCTG-N9831. May 2005 Update. Presented at the 41st American Society of Clinical Oncology Annual Meeting, 2005 May 13-17, Orlando, FL [http://www.asco.org/ac/ 1,10003,_12-002511-00_18-0034-00_19-005815-00_21-001,00.asp]
9. Perez EA et al. (2007) Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 25 (18 Suppl): LBA512
10. Slamon D et al. (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study [abstract #1]. Breast Cancer Res Treat 94 (Suppl 1): S5
11. Slamon D et al. (2006) BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients. Breast Cancer Res Treat 100: S2
12. Joensuu H et al. (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354: 809-820
13. Baselga J et al. (1999) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 59: 2825-2831
14. Pegram M et al. (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251
15. Seidman A et al. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-1221
16. Rastogi P et al. (2007) Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC)→paclitaxel (T) vs AC→T with trastuzumab (H). J Clin Oncol 25 (18 Suppl): LBA512
17. Suter TM et al. (2007) Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant trial. J Clin Oncol 25: 1-8
18. Pietras RJ et al. (1999) Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59: 1347-1355
19. Halyard MY et al. (2006) Adjuvant radiotherapy and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831. J Clin Oncol 24 (18 Suppl): LBA523
20. Leyland-Jones B et al. (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21: 3965-3971
21. Early Breast Cancer Trialists' Collaborative Group: (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 265: 1687-1717
22. Goldhirsh A et al. (2007) Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144
23. Gelber RD et al. (2003) Tailoring adjuvant treatments for the individual breast cancer patient. The Breast 12: 558-568
24. Johnston SR et al. (2007) Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J Steroid Biochem Mol Biol 106: 180-186
25. Osborne CK et al. (2003) Role of estrogen receptor coactivator AIB1 (SRC3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95: 353-361
26. Mackey JR et al. (2006) Trastuzumab prolongs progression-free survival in hormone-dependent and HER-2 positive metastatic breast cancer. Presented at the San Antonio Breast Cancer Symposium. 2006 December 14-17 [http://www.abstracts2view.com/sabcs06/ view.php?nu=SABCS06L_665]
27. Durbecq V et al. (2004) Correlation between topoisomerase II-alpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol 25: 1473-1479
28. Durbecq V et al. (2004) Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 3: 1207-1214
29. Cardoso F et al. (2004) Correlation between complete response to anthracycline-based chemotherapy and topoisomerase-II gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 24: 201-209
30. Park K et al. (2006) Topoisomerase II-alpha gene deletion is not as frequent as its amplification in breast cancer. Breast Cancer Res Treat 98: 337-342
31. Tanner M et al. (2006) Topoisomerase II-alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24 2409-2411
32. Knoop AS et al. (2005) Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophoshamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23: 7483-7490
33. Coon JS et al. (2002) Amplification and overexpression of topoisomerase II-alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8: 1061-1067
34. Di Leo A et al. (2002) HER-2 amplification and topoisomerase II-alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8: 1107-1116
35. Park K et al. (2003) Topoisomerase II-alpha (topoII) and HER-2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39: 631-634
36. Jarvinen TA and Liu ET (2003) Her-2/neu and topoisomerase II alpha in breast cancer. Breast Cancer Res 78: 299-311
37. Withoff S et al. (1996) Selection of a subpopulation with fever DNA topoisomerase II α gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 74: 502-507
38. Jarvinen TA et al. (1999) Characterisation of topoisomerase II α gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26: 142-150
39. Gopalakrishnan S and Linnane J (2005) Adjuvant trastuzumab for breast cancer: The other side of the coin. BMJ 331: 1202-1203
40. Imai H et al. (2007) Economic evaluation of the prevention and treatment of breast cancer-present status and open issues. Breast Cancer 14: 81-87
41. Liberato NL et al. (2007) Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 25: 625-633
42. Shiroiwa T et al. (2007) The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: Based on 2-year follow-up HERA trial data. Breast Cancer Res Treat 109: 559-566
43. Neyt M et al. (2006) An economic evaluation of Herceptin in adjuvant setting: The Breast Cancer International Research Group 006 trial. Ann Oncol 17: 381-390
44. Millar JA and Millward MJ (2007) Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: A lifetime model. Pharmacoeconomics 25: 429-442
45. Nagy P et al. (2005) Decreased accessibility and lack of activation or ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65: 473-482
46. Nagata Y et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127
47. Nahta R et al. (2004) p27(kip1) downregulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64 3981-3986
48. Lu YH et al. (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Nat Cancer Inst 93: 1852-1857
49. Nahta R et al. (2005) Insulin-like growth factor-I receptor/ human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65 11118-11128